Par Drugs And Chemicals liquidity ratios

·UnclassifiedChart ›

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

7.24×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
4.68×	4.68×	3.31×	4.79×	3.53×
4.29×	4.29×	2.94×	4.46×	3.15×
36.4	41.8	27.6	36.7	22.2
51.0	50.6	38.3	47.2	35.4

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

PAR₹120.70

Par Drugs And Chemicals Limited

· Unclassified

₹ CrorePeersBALAXI CROWN STEELCITY HINDCON LATTEYS HECPROJECT AIROLAM GROBTEAMcap ₹149 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	7.24
Current Ratio	3.53	4.79	3.31	4.68	4.68
Quick Ratio	3.15	4.46	2.94	4.29	4.29
Cash, Equiv & ST Investments	22.2	36.7	27.6	41.8	36.4
Working Capital	35.4	47.2	38.3	50.6	51.0

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.